183 related articles for article (PubMed ID: 26622542)
1. Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.
Kobayashi H; Sugimoto H; Onishi S; Nakano K
Oncol Lett; 2015 Aug; 10(2):612-618. PubMed ID: 26622542
[TBL] [Abstract][Full Text] [Related]
2. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of combined detection of HNF-1β and Napsin A in the diagnosis of ovarian clear cell carcinoma].
Wang J; Li Q; Cheng X; Xiong K; Qi Q; Huang W
Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):874-8. PubMed ID: 26888504
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of p53 regulation of oxidative stress in skeletal muscle.
Beyfuss K; Hood DA
Redox Rep; 2018 Dec; 23(1):100-117. PubMed ID: 29298131
[TBL] [Abstract][Full Text] [Related]
5. Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.
Huang CC; Cheng SH; Wu CH; Li WY; Wang JS; Kung ML; Chu TH; Huang ST; Feng CT; Huang SC; Tai MH
Oncogene; 2019 Apr; 38(17):3201-3215. PubMed ID: 30626939
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 2 expression may be involved in transformation of ovarian endometrioma to clear cell carcinoma of the ovary.
Taniguchi F; Itamochi H; Harada T; Terakawa N
Int J Gynecol Cancer; 2013 Jun; 23(5):791-6. PubMed ID: 23640291
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
Ping H; Guo L; Xi J; Wang D
Tumour Biol; 2017 Jun; 39(6):1010428317713389. PubMed ID: 28651497
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of dual detection of hepatocyte nuclear factor 1 beta (HNF-1β) and napsin A for diagnosing ovarian clear cell carcinoma.
Li Q; Zeng X; Cheng X; Zhang J; Ji J; Wang J; Xiong K; Qi Q; Huang W
Int J Clin Exp Pathol; 2015; 8(7):8305-10. PubMed ID: 26339401
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma.
Lai X; Umbricht CB; Fisher K; Bishop J; Shi Q; Chen S
J Proteomics; 2017 Aug; 166():59-67. PubMed ID: 28709933
[TBL] [Abstract][Full Text] [Related]
11. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species.
Mizuno T; Suzuki N; Makino H; Furui T; Morii E; Aoki H; Kunisada T; Yano M; Kuji S; Hirashima Y; Arakawa A; Nishio S; Ushijima K; Ito K; Itani Y; Morishige K
Gynecol Oncol; 2015 May; 137(2):299-305. PubMed ID: 25541259
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review).
Kobayashi H; Kajiwara H; Kanayama S; Yamada Y; Furukawa N; Noguchi T; Haruta S; Yoshida S; Sakata M; Sado T; Oi H
Oncol Rep; 2009 Aug; 22(2):233-40. PubMed ID: 19578761
[TBL] [Abstract][Full Text] [Related]
15. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
16. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary.
Kobayashi H; Shigetomi H; Yoshimoto C
Oncol Lett; 2015 Aug; 10(2):571-576. PubMed ID: 26622535
[TBL] [Abstract][Full Text] [Related]
18. [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].
Jiang XL; Gao JC; Jiang L; Zhang PX; Kang TJ; Sun Q; Qi WJ; Zhang QP; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2019 Aug; 54(8):541-547. PubMed ID: 31461811
[No Abstract] [Full Text] [Related]
19. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF
Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
[TBL] [Abstract][Full Text] [Related]
20. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
